Showing results (421-430 of 436) with videos related to

Sort By:
Pageof 44
Plos Genetics|October 3, 2007
Genome-wide patterns of nucleotide polymorphism in domesticated riceAna L Caicedo, Scott H Williamson, Ryan D Hernandez, et al.
Pediatrics|July 14, 2017
Controlling Phlebotomy Volume Diminishes PICU Transfusion: Implementation Processes and ImpactKatherine Steffen, Allan Doctor, Julie Hoerr, et al.
Obstetrics and Gynecology|July 11, 2024
Duration of Induction of Labor for Second-Trimester Medication Abortion and Adverse OutcomesAshish Premkumar, Vanya Manthena, Jocelyn Wascher, et al.
Epidemiology and Infection|May 5, 2006
Risk factors for encephalitis and death from West Nile virus infectionK Murray, S Baraniuk, M Resnick, et al.
Advanced Healthcare Materials|December 5, 2012
Core-shell hydrogel microcapsules for improved islets encapsulationMinglin Ma, Alan Chiu, Gaurav Sahay, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|January 23, 2008
An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritisD D Lazarus, E G Doyle, S G Bernier, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 17, 2020
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical TrialJohn P Hanrahan, Ian H de Boer, George L Bakris, et al.
EJNMMI Research|February 16, 2024
Synthesis and preclinical evaluation of [11C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptorAntonia A Högnäsbacka, Alex J Poot, Christophe Plisson, et al.
Diabetologia|December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertensionJohn P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Structure-Based Design of A-1293102, a Potent and Selective BCL-XL InhibitorZhi-Fu Tao, Xilu Wang, Jun Chen, et al.
Pageof 44